IP Library › Granted Patent US 12,234,483
Granted Patent B2
US 12,234,483 · App. 18/302,043 · Granted Feb 25, 2025

Methods of decreasing the galactose content of a recombinant glycoprotein expressed in CHO cells

Inventor: Jun Tian (Westford, MA)
Assignee: Bristol-Myers Squibb Company
C12N5/0682C12N5/0031C12P21/005C12N2500/22C12N2500/24C12N2500/32C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,483
App. No.
18/302,043
Granted
Feb 25, 2025
Kind
B2
Abstract

In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.

Claims (14)

1. A method of decreasing galactose content of a recombinant glycoprotein comprising:

culturing a Chinese Hamster Ovary (CHO) host cell in a suitable cell culture medium, wherein the CHO host cell comprises an expression vector encoding a glycoprotein;

adding at least about 2 g/L asparagine and less than about 0.01 mg/L zinc to the cell culture medium,

wherein the cell culture medium is maintained under following conditions:

a) pH between 6.5-7.5;

b) dissolved oxygen between 5% and 90% of air saturation;

c) carbon dioxide between 10 mmHg and 150 mmHg; and

d) temperature between 30° C. and 37° C.; and

wherein the galactose content of the expressed glycoprotein is decreased.

2. The method of claim 1 , wherein the cell culture medium is chemically defined.

3. The method of claim 2 , wherein the chemically defined cell culture medium is basal medium.

4. The method of claim 3 , wherein the chemically defined basal medium does not contain added serum or hydrolysates.

5. The method of claim 3 , wherein the chemically defined basal medium is protein-free.

6. The process according to claim 1 , wherein the glycoprotein is a recombinant antibody, antibody fragment or fusion protein.

Continuity (4)
Division 17830794 · Jun 2, 2022
Division 15774138
Provisional Application 62252849 · Nov 9, 2015
Related Publication 20230250399A1 · Aug 10, 2023
References Cited (13)
US 9062106B2 · Bengea et al. · 2015 [cited by applicant]
US 11401509B2 · Tian · 2022 [cited by examiner]
US 11655457B2 · Tian · 2023 [cited by examiner]
US 20080070280A1 · Schilling et al. · 2008 [cited by applicant]
US 20140273092A1 · Flikweert · 2014 [cited by examiner]
WO 199961650 · 1999 [cited by applicant]
WO 2007050498 · 2007 [cited by applicant]
WO 20090126564 · 2009 [cited by applicant]
WO 20110134921 · 2011 [cited by applicant]
WO 20140062535 · 2014 [cited by applicant]
Bruhlmann D. et al. “Tailoring recombinant protein quality by rational media design”, vol. 31, No. 3, Apr. 29, 2015 (Apr. 29, 2015), pp. 615-629. [cited by applicant]
Gramer M.J. et al.: “Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose”, vol. 108, No. 7, Jul. 2011 (Jul. 2011), pp. 1591-1602. [cited by applicant]
Hossler P. et al.: “Targeted shifting of protein glycosylation profiles inmammalian cell culture through media supplementation of colbalt”, J. Glycobiol., vol. 3, No. 1, 108, Sep. 17, 2014 (Sep. 17, 2014), pp. 1-9. [cited by applicant]